Abundant Produce joins forces with Australia’s leading healthcare service provider
Abundant Produce (ASX:ABT) today revealed it has penned a sales, marketing and distribution agreement with HealthOne, which will commence in Australia.
This deal will see HealthOne representing Abundant Natural Health (ANH) products in Australian pharmacies servicing independent pharmacies and gift outlets.
HealthOne is Australia’s fastest growing healthcare commercial partner, with specialist national sales teams servicing all facets of the pharmacy channel, leveraging robust relationships with wholesalers, key banner groups, individual pharmacies and healthcare professionals.
It has been active in the Australian healthcare marketplace for over 15 years, representing market-leading companies and brands. Its multi‐dimensional approach encompasses brand strategy, marketing services, sales representation, merchandising, and staff education.
ABT CEO, Shanan Birkin, said: “Importantly, our agreement with HealthOne moves us from an online platform to a bricks-and-mortar presence with a partner that has the ability to penetrate the Australian market, using its in‐depth understanding of the intricacies of pharmacy product distribution.”
Birkin added: “This helps us to build on our objective of becoming a number-one player in the natural healthcare arena and the ethical brand of choice. We believe our 100% Australian grown, made and owned products are a game changer in our target markets.”
HealthOne managing director, Seona Wallace, commented: “We’re excited about representing these new innovative products, which are developed and produced locally by ANH in collaboration with the University of Sydney and the University of NSW.”
“Having science-based products of this calibre, particularly the new body and skin ranges, will be a great offering to the majors,” said Wallace.
It should be noted here that ABT remains a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.